FATE THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

03 Mar 2025 10:33:37 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

28 Feb 2025 06:45:41 By NetDania Notify

Fate Therapeutics to Present at Upcoming Investor Conferences

14 Feb 2025 13:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

04 Feb 2025 13:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

14 Jan 2025 06:45:18 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

13 Jan 2025 06:45:04 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

10 Jan 2025 07:22:09 By NetDania Notify

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2025 13:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

30 Dec 2024 06:52:19 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

26 Dec 2024 10:03:48 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

23 Dec 2024 07:24:21 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

19 Dec 2024 07:10:18 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

18 Dec 2024 06:46:00 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

13 Dec 2024 06:45:20 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

12 Dec 2024 07:17:16 By NetDania Notify

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

09 Dec 2024 13:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

03 Dec 2024 13:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Leadership Transition

29 Nov 2024 10:05:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming December Investor Conferences

26 Nov 2024 13:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

18 Nov 2024 05:05:00 By Nasdaq GlobeNewswire